Clinical trial
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
NCT00142168 · Dana-Farber Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00142168 |
|---|---|
| Title | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia |
| Official title | Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Brigham and Women's Hospital Celgene Corporation Industry Genentech, Inc. |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom's Macroglobulinemia |
| Intervention type | Drug |
| Interventions | CC-5103 (lenalidomide), Rituximab |
| Enrollment | 16 |
| Start date | Sep 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | Apr 1, 2008 |
| First posted | Sep 2, 2005 |
| Last update posted | Apr 21, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: